Book Cover
Home  |   Healthcare   |  Yttrium-90 Microspheres Market

Yttrium-90 Microspheres Market Size, Share, Growth, and Industry Analysis, By Type (Resin Microspheres, Glass Microspheres, Carbon Microspheres), By Application (Liver Cancer Treatment, Other Cancer Treatments), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Yttrium-90 Microspheres Market Overview

The global Yttrium-90 Microspheres Market is anticipated to grow from USD 300.48 Million in 2026 to USD 673.49 Million by 2035, registering a CAGR of 9.38% during the forecast period 2026-2035.

The Yttrium-90 Microspheres Market is advancing as interventional oncology teams increasingly consider targeted radioembolization for selected patients with primary and metastatic liver malignancies. Yttrium-90 microspheres deliver beta radiation through the hepatic arterial circulation, allowing concentrated treatment of liver tumors while limiting unnecessary irradiation of surrounding tissue. Yttrium-90 has a physical half-life of approximately 64 hours, making treatment preparation, activity calibration, and administration timing essential operational considerations. Commercially established technologies include resin and glass microspheres, while carbon-based formulations remain an investigational material category without comparable established clinical commercialization. Recent developments emphasize individualized radiation dosimetry, multidisciplinary treatment planning, and improved clinical evidence. Greater integration of interventional radiology, nuclear medicine, medical physics, and oncology is strengthening the clinical infrastructure supporting selective internal radiation therapy.

The United States represents an important market for Yttrium-90 microspheres, supported by advanced cancer treatment centers, established interventional radiology capabilities, and regulatory approvals for liver-directed therapies. The country has 2 major commercially established Yttrium-90 microsphere platforms represented by Sirtex Medical and Boston Scientific Corporation. Their respective resin and glass technologies support different treatment workflows and dosimetry considerations. Clinical adoption is influenced by physician training, radiation safety infrastructure, patient eligibility, and institutional reimbursement arrangements. United States hospitals increasingly emphasize personalized treatment planning and documented clinical outcomes, particularly for hepatocellular carcinoma. 

Global Yttrium-90 Microspheres Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Key Market Driver: Increasing adoption of personalized liver cancer treatment strengthens Yttrium-90 microsphere demand, with approximately 74% of patients in the PROACTIF hepatocellular carcinoma cohort receiving multicompartment dosimetry to support targeted radiation planning.
  • Major Market Restraint: Complex radiation planning, strict patient eligibility requirements, and potential treatment complications restrict wider adoption, with the PROACTIF hepatocellular carcinoma study reporting serious adverse events in approximately 8% of treated patients.
  • Emerging Trends: Personalized radioembolization and advanced treatment planning are improving clinical outcomes, with the DOORwaY90 study reporting a 90% complete response rate among evaluable patients receiving resin microspheres for unresectable hepatocellular carcinoma.
  • Regional Leadership: North America leads the Yttrium-90 Microspheres Market with approximately 41% of the provisional global market distribution, supported by advanced oncology infrastructure, established interventional radiology facilities, and specialized liver cancer treatment services.
  • Competitive Landscape: Sirtex Medical remains a prominent supplier of resin-based Yttrium-90 microspheres, supported by clinical evidence demonstrating a 99% best overall response rate in the DOORwaY90 study involving selected hepatocellular carcinoma patients.
  • Market Segmentation: Resin Microspheres lead the product type distribution with approximately 58% market share in the referenced analysis, supported by established radioembolization applications, targeted radiation delivery, and specialized liver cancer treatment capabilities.
  • Recent Development: The PROACTIF glass microsphere study published in May 2026 reported serious treatment-related adverse events in approximately 4% of hepatocellular carcinoma patients, strengthening clinical evidence concerning radioembolization safety and treatment monitoring.

The Yttrium-90 Microspheres Market is increasingly influenced by personalized dosimetry, advanced treatment planning, and growing clinical interest in selective radiation delivery for liver cancer. Approximately 74% of patients in the PROACTIF hepatocellular carcinoma cohort underwent multicompartment dosimetry, highlighting the importance of calculating radiation exposure separately for tumor and healthy liver tissue. Contemporary treatment approaches use detailed imaging, catheter-based vascular assessment, and medical physics calculations to develop patient-specific treatment plans. Manufacturers are supporting clinical teams through improved treatment planning tools and professional education. 

Another important trend involves stronger clinical evidence supporting Yttrium-90 radioembolization in appropriately selected patients. The DOORwaY90 study reported a 90% complete response rate among evaluable patients receiving SIR-Spheres resin microspheres for unresectable hepatocellular carcinoma. Such results encourage further investigation of radioembolization within multidisciplinary liver cancer management. Clinical centers increasingly evaluate tumor characteristics, liver function, vascular anatomy, and previous treatment history before recommending therapy. Research also examines the relationship between absorbed radiation dose and subsequent treatment outcomes. 

Yttrium-90 Microspheres Market Dynamics

Driver

"Growing clinical adoption of targeted liver cancer therapy supports microsphere demand."

The increasing need for effective liver-directed cancer treatment represents a central driver of the Yttrium-90 Microspheres Market. Approximately 74% of patients in the PROACTIF hepatocellular carcinoma cohort received multicompartment dosimetry, highlighting the growing importance of personalized radiation treatment planning. The study evaluated 989 patients treated using glass microspheres, demonstrating the scale of contemporary clinical investigation into radioembolization. Yttrium-90 therapy allows interventional specialists to deliver radiation through selected hepatic arterial branches rather than relying on external radiation alone. This approach may be considered for patients whose disease characteristics and liver function satisfy appropriate treatment criteria. 

Development of stronger clinical evidence also supports treatment adoption and reimbursement discussions. The PROACTIF cohort reported a median overall survival of approximately 22 months across its hepatocellular carcinoma population, although individual outcomes varied substantially according to disease characteristics and treatment conditions. These findings contribute to understanding the potential role of radioembolization in contemporary liver cancer management. Clinical institutions increasingly evaluate real-world evidence alongside prospective trials when considering treatment protocols.

Restraint

"Complex clinical qualification and radiation safety requirements restrict broader treatment adoption."

Specialized treatment infrastructure and demanding patient eligibility requirements remain important restraints affecting the Yttrium-90 Microspheres Market. The PROACTIF hepatocellular carcinoma analysis reported serious adverse events in approximately 8% of patients, demonstrating the importance of careful clinical monitoring and risk assessment. Radioembolization requires multidisciplinary participation from interventional radiologists, nuclear medicine specialists, medical physicists, and oncology physicians. Before treatment, clinicians must evaluate hepatic arterial anatomy, liver function, tumor distribution, and potential radiation exposure to non-target tissues. 

Patient-specific clinical limitations also influence the potential treatment population. The PROACTIF analysis documented serious treatment-related adverse events in approximately 4% of patients with hepatocellular carcinoma, emphasizing the need for appropriate medical supervision. Treatment risks may include liver injury, gastrointestinal complications, fatigue, and other effects associated with radiation delivery or underlying disease. Clinicians must carefully distinguish expected treatment effects from complications requiring intervention. 

Opportunity

"Personalized dosimetry and expanding clinical evidence create new treatment opportunities."

Advances in individualized radiation dose planning create important opportunities for Yttrium-90 microsphere manufacturers. The PROACTIF analysis demonstrated a median overall survival of approximately 31 months among patients receiving a tumor absorbed dose of at least 400 Gy, compared with shorter survival in the lower-dose comparison group. This observational association supports further investigation of dosimetry-guided treatment strategies, although it does not establish identical benefits for every patient. 

Broader clinical research also creates opportunities for expanding treatment knowledge across different liver malignancies. The PROACTIF registry enrolled 1,259 patients with various liver cancer diagnoses, demonstrating substantial clinical interest in evaluating glass microsphere therapy under real-world conditions. Research involving hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and colorectal liver metastases may inform future treatment guidelines and product development. However, regulatory authorization must be evaluated separately for each indication and geographic market. Hospitals are increasingly interested in treatment approaches supported by prospective clinical data and clear safety documentation.

Challenge

"Accurate radiation delivery and consistent patient selection remain critical clinical challenges."

Achieving appropriate radiation distribution within liver tumors represents a major technical challenge in Yttrium-90 microsphere therapy. Approximately 54% of patients in the PROACTIF hepatocellular carcinoma cohort received selective administration, illustrating the importance of carefully planned catheter positioning and targeted treatment delivery. Variations in tumor vascularity, arterial branching, and liver anatomy can influence microsphere distribution. Clinical teams must evaluate potential non-target deposition and determine suitable treatment activity before administration. 

Ensuring consistency between clinical research findings and routine hospital practice creates another important challenge. The PROACTIF hepatocellular carcinoma analysis included patients with different disease stages, including approximately 35% with portal vein tumor thrombosis. Such clinical diversity can influence survival, treatment planning, and complication risk. Results from specialized centers may not translate directly into outcomes at institutions with different levels of experience. 

Yttrium-90 Microspheres Market Segmentation

Global Yttrium-90 Microspheres Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Resin Microspheres: Resin Microspheres represent the leading product category within the Yttrium-90 Microspheres Market. The segment accounts for approximately 58% of the product market distribution reported in the referenced market analysis, reflecting established adoption of resin-based radioembolization technologies for selected liver malignancies. Commercial resin microspheres generally measure approximately 20–60 micrometers and are administered through the hepatic arterial circulation to deliver targeted beta radiation. Sirtex Medical markets SIR-Spheres, a commercially established resin-based treatment platform supported by clinical studies and regulatory authorizations. 

Glass Microspheres: Glass Microspheres constitute an important established product category within the Yttrium-90 Microspheres Market. The segment accounts for approximately 36% of the product distribution in the referenced market analysis, supported by the clinical use of glass-based radioembolization technologies for selected liver cancer indications. TheraSphere glass microspheres generally measure approximately 20–30 micrometers and incorporate radioactive yttrium within a glass matrix. Boston Scientific Corporation supplies this technology to qualified healthcare institutions. 

Carbon Microspheres: Carbon Microspheres represent an investigational material category within the Yttrium-90 Microspheres Market. The referenced market analysis assigns approximately 6% of the product distribution to carbon-based microspheres, although this figure should be treated as an unverified market estimate rather than evidence of established commercial treatment use. Carbon-based materials have been investigated as potential radioactive carriers for targeted radiation delivery. Development considerations include material biocompatibility, radionuclide retention, particle stability, and predictable distribution within selected tissues. 

By Applications

Liver Cancer Treatment: Liver Cancer Treatment represents the dominant application segment within the Yttrium-90 Microspheres Market. The referenced market analysis attributes approximately 77% of the application distribution to liver cancer treatment, reflecting the established role of selective internal radiation therapy in managing certain primary hepatic malignancies. Yttrium-90 microspheres are delivered through the hepatic arterial circulation to concentrate radiation within selected tumor-bearing regions. The PROACTIF study evaluated 989 patients with hepatocellular carcinoma treated using glass microspheres, demonstrating substantial clinical investigation into radioembolization outcomes. 

Other Cancer Treatments: Other Cancer Treatments represent a specialized application category within the Yttrium-90 Microspheres Market. The referenced market analysis assigns approximately 23% of its application distribution to other cancer treatments, including selected liver-directed treatment of metastatic malignancies and investigational applications. Yttrium-90 radioembolization has been evaluated in patients with colorectal liver metastases, intrahepatic cholangiocarcinoma, and other hepatic tumors when treatment characteristics support arterial radiation delivery. The PROACTIF registry included 1,259 patients with different liver cancer diagnoses, contributing clinical evidence concerning treatment outcomes and patient selection. 

Yttrium-90 Microspheres Market Regional Outlook

Global Yttrium-90 Microspheres Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America represents the leading geographic segment within the Yttrium-90 Microspheres Market. The region accounts for approximately 41% of the provisional global market distribution, supported by advanced oncology infrastructure, established interventional radiology capabilities, and specialized cancer treatment institutions. The United States serves as the principal regional center for clinical research, regulatory activity, and radioembolization technology development. Sirtex Medical and Boston Scientific Corporation supply established resin and glass microsphere platforms for defined liver cancer indications. 

Continued clinical research and technological advancement strengthen North America's position within the global radioembolization industry. The region's provisional 41% market share reflects the importance assigned to its established treatment infrastructure in the regional distribution. Regulatory developments during 2026 involving TheraSphere dosimetry and digital treatment planning illustrate continued interest in improving procedural consistency. Specialized hospitals increasingly evaluate radiation distribution, patient eligibility, and treatment outcomes using advanced imaging and medical physics methodologies. 

Europe

Europe maintains an established position in the Yttrium-90 Microspheres Market through specialized oncology institutions, advanced nuclear medicine capabilities, and extensive interventional radiology research. The region accounts for approximately 29% of the provisional global market distribution, supported by clinical activity in Germany, France, Italy, the United Kingdom, and other healthcare markets. European medical institutions participate in prospective studies investigating radioembolization effectiveness, treatment safety, and personalized radiation dosimetry. 

European clinical research continues to improve understanding of treatment outcomes and radiation dose optimization in liver cancer management. The region's provisional 29% market share reflects its established specialist treatment capabilities and research participation. The PROACTIF hepatocellular carcinoma analysis evaluated patients receiving glass microsphere radioembolization and examined associations between absorbed radiation dose and survival. These findings support further investigation of individualized treatment planning and patient selection. 

Asia-Pacific

Asia-Pacific represents an important regional market for Yttrium-90 microsphere technologies, supported by expanding specialist healthcare infrastructure and considerable demand for liver cancer treatment services. The region accounts for approximately 22% of the provisional global market distribution, reflecting clinical adoption across established and developing interventional oncology centers. China, Japan, South Korea, Australia, and Singapore participate in advanced medical technology development and specialist cancer treatment. Regional healthcare systems increasingly evaluate targeted liver-directed radiation therapy for appropriately selected patients. Adoption depends on national regulatory requirements, treatment reimbursement, specialist expertise, and the availability of qualified medical facilities.

Investment in cancer treatment infrastructure and clinical education is expected to support continued technological development across Asia-Pacific. The region's provisional 22% market share reflects its position within the geographic distribution. Hospitals introducing Yttrium-90 radioembolization require dependable radioactive material logistics, specialized imaging equipment, and multidisciplinary clinical expertise. Resin and glass microspheres have different preparation and administration requirements, making product-specific training essential. .

Middle East and Africa

Middle East and Africa represents a developing regional market for Yttrium-90 microsphere technologies. A provisional allocation of approximately 5% is assigned to the region within the five-region global market distribution, reflecting selected specialist cancer centers and increasing investment in advanced oncology services. Healthcare institutions in several Middle Eastern countries are expanding interventional radiology and nuclear medicine capabilities, while access to advanced treatment remains uneven across Africa. Establishing a radioembolization program requires qualified medical teams, appropriate radiation safety infrastructure, and reliable access to approved products. Patient eligibility, treatment affordability, and specialist availability influence clinical adoption. 

Continued healthcare investment and specialized medical training may strengthen Yttrium-90 microsphere adoption across Middle East and Africa. The region's provisional 5% allocation represents its assigned position within the five-region market distribution and requires independent validation. Manufacturers supplying these markets must address transportation requirements, isotope handling, regulatory authorization, and clinical support capabilities. The physical half-life of Yttrium-90 makes reliable distribution and coordinated treatment scheduling particularly important. Hospitals developing radioembolization services must also establish appropriate patient assessment and radiation protection procedures. 

Rest of the World

Rest of the World includes remaining geographic markets outside the separately identified regions, particularly relevant interventional oncology activities across Latin America. A provisional allocation of approximately 3% is assigned to this category within the five-region global market distribution, reflecting developing specialist cancer treatment services and emerging medical technology adoption. Healthcare institutions in these markets are expanding oncology capabilities according to local infrastructure and regulatory conditions. Yttrium-90 radioembolization requires qualified treatment teams, dependable radioactive material distribution, and appropriate hospital facilities. 

Expansion of specialized oncology infrastructure may create additional opportunities for Yttrium-90 microsphere suppliers in remaining geographic markets. The category's provisional 3% market allocation reflects its assigned share within the five-region distribution and requires confirmation using comprehensive market data. Medical institutions evaluating radioembolization must consider clinical indications, product availability, trained personnel, and radiation safety requirements. Manufacturers can support regional development through professional education, dependable supply arrangements, and technical assistance. 

List of Top Yttrium-90 Microspheres Market Companies

  • Sirtex Medical
  • Boston Scientific Corporation

Top Two Companies with Highest Market Share

  • Sirtex Medical: A leading supplier of resin-based Yttrium-90 microspheres, supported by clinical research reporting a 99% best overall response rate in the DOORwaY90 study.
  • Boston Scientific Corporation: A leading supplier of glass-based Yttrium-90 microspheres, supported by the PROACTIF study reporting approximately 74% use of multicompartment dosimetry among hepatocellular carcinoma patients.

Investment Analysis and Opportunities

Investment opportunities in the Yttrium-90 Microspheres Market are closely associated with specialist oncology infrastructure, personalized treatment planning, and clinical evidence generation. The PROACTIF registry enrolled 1,259 patients, demonstrating the importance of large prospective datasets in evaluating contemporary radioembolization practice. Hospitals investing in advanced interventional radiology services require trained personnel, specialized imaging equipment, and reliable radiation safety infrastructure. Manufacturers can strengthen their competitive position through physician education, dosimetry software, and dependable clinical support. 

Further investment opportunities arise from advances in imaging-based dosimetry and collaborative clinical research. In the PROACTIF hepatocellular carcinoma analysis, approximately 74% of patients received multicompartment dosimetry, illustrating the increasing importance of individualized treatment calculations. Technology developers are investigating methods that simplify image interpretation, improve radiation dose estimation, and support multidisciplinary decision-making. 

New Product Development

New product development in the Yttrium-90 Microspheres Market increasingly emphasizes improved radiation dose planning and software-supported treatment preparation. Boston Scientific received regulatory clearance in March 2026 for its TheraSphere 360 Y-90 Management Platform, representing an important development in digital radioembolization workflow support. Advanced software tools can assist clinical teams with imaging evaluation, procedural documentation, and treatment planning. Separately, regulatory activity during February 2026 addressed multicompartment dosimetry in TheraSphere labeling. 

Clinical evidence development remains another important contributor to product differentiation. Sirtex Medical reported a 99% best overall response rate in the DOORwaY90 study during April 2026, strengthening the available evidence concerning resin microsphere radioembolization in selected patients with hepatocellular carcinoma. Boston Scientific-supported research also generated detailed real-world findings concerning glass microsphere treatment and patient outcomes. 

Five Recent Developments

  • February 2026 – Boston Scientific Receives Updated TheraSphere Dosimetry Authorization: A United States regulatory supplement was approved for TheraSphere, incorporating multicompartment dosimetry into product documentation and supporting separate evaluation of tumor and healthy tissue radiation exposure.
  • March 2026 – Boston Scientific Advances Digital Radioembolization Treatment Planning: The TheraSphere 360 Y-90 Management Platform received United States regulatory clearance, supporting development of software-based workflows for treatment planning and management of glass microsphere radioembolization.
  • April 2026 – Sirtex Medical Announces Major Clinical Study Results: Sirtex Medical reported a 99% best overall response rate in the DOORwaY90 study, providing additional clinical evidence for resin microsphere treatment in the evaluated hepatocellular carcinoma population.
  • April 2026 – Boston Scientific Supported PROACTIF Research Publication Released: The prospective PROACTIF hepatocellular carcinoma analysis was published online, reporting outcomes from 989 patients treated with TheraSphere glass microspheres and examining associations between radiation dose and survival.
  • May 2026 – PROACTIF Glass Microsphere Study Receives Journal Publication: The PROACTIF analysis appeared in the May issue of eClinicalMedicine, reporting serious treatment-related adverse events in approximately 4% of patients and contributing evidence concerning real-world radioembolization safety.

Future Outlook

The Yttrium-90 Microspheres Market is expected to benefit from continued progress in targeted liver cancer treatment, personalized radiation dosimetry, and multidisciplinary interventional oncology. Manufacturers will prioritize improved clinical evidence, dependable microsphere delivery, and increasingly sophisticated treatment planning technologies. Development of digital dosimetry platforms may help healthcare professionals evaluate radiation distribution and improve procedural consistency. Greater emphasis on prospective clinical studies and patient-specific treatment selection will continue shaping professional adoption. Resin and glass microspheres are expected to remain the principal commercially established material categories, while investigational formulations will require extensive safety evaluation and clinical evidence before routine adoption. 

Regional development will remain influenced by specialist healthcare infrastructure, regulatory authorization, reimbursement conditions, and availability of trained medical professionals. North America and Europe will continue contributing through clinical research and advanced treatment services, while Asia-Pacific may provide opportunities for expanded specialist oncology capabilities. Emerging healthcare markets will require investment in radiation safety, multidisciplinary training, and dependable medical technology distribution. Continued collaboration between device manufacturers, hospitals, research institutions, and regulatory authorities will be important for improving treatment quality and access. 

Yttrium-90 Microspheres Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 300.48 Million in 2026

Market Size Value By

USD 673.49 Million by 2035

Growth Rate

CAGR of 9.38% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Resin Microspheres
  • Glass Microspheres
  • Carbon Microspheres

By Application :

  • Liver Cancer Treatment
  • Other Cancer Treatments

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Yttrium-90 Microspheres Market is expected to reach USD 673.49 Million by 2035.

The Yttrium-90 Microspheres Market is expected to exhibit a CAGR of 9.38% by 2035.

In 2026, the Yttrium-90 Microspheres Market value will reach at USD 300.48 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified